News for Minerva Neurosciences Inc (4MN.MU)

LOS ANGELES, Feb. 8, 2021 /PRNewswire/ --  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit

WHY: NEW YORK, Feb. 06, 2021 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. between May 15, 2017 and November 30,...

WHY: NEW YORK, Feb. 06, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva...

WHY: NEW YORK, Feb. 06, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva ...

NEW YORK, Feb.?5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global... | February 6, 2021

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV)...

NEW YORK, Feb. 5, 2021 /PRNewswire/ -- WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District... | February 6, 2021

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United

NEW YORK, NY / ACCESSWIRE / February 2, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or "the Company") (NASDAQ:NERV) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Minerva securities between May 15, 2017 and November 30, 2020, both dates inclusive (the "Class Period").

Today's Daily Dose brings you news about another Alzheimer's disease drug failure, encouraging data of Aclaris' rheumatoid arthritis trial; Royalty Pharma/Minerva deal; Gritstone joining the COVID-19 vaccine race; and FDA imposing a clinical hold on Histogen's planned trial of HST-003 for knee cartilage regeneration.